Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy.
Ann Surg Oncol. 2021 Jul;28(7):3616-3626. doi: 10.1245/s10434-020-09302-y. Epub 2020 Nov 9.
Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS).
Data for stage IB2-IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed.
Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical response to CT/RT. The 5-year disease-free survival (DFS) was 73.7% in the O-RS patients and 73.0% in the MI-RS patients (HR 1.034, 95% CI 0.708-1.512, p = 0.861). The 5-year locoregional recurrence rate was 12.5% (O-RS) versus 15.2% (MI-RS) (HR 1.174, 95% CI 0.656-2.104, p = 0.588). The 5-year disease-specific survival (DSS) was 80.4% in O-RS patients and 85.3% in the MI-RS group (HR 0.731, 95% CI 0.438-1.220, p = 0.228). Estimated blood loss was lower in the MI-RS group (p < 0.001), as was length of hospital stay (p < 0.001). Early postoperative complications occurred in 77 patients (33.3%) in the O-RS group versus 88 patients (38.1%) in the MI-RS group (p = 0.331). Fifty-six (24.2%) patients experienced late postoperative complications in the O-RS group, versus 61 patients (26.4%) in the MI-RS group (p = 0.668).
MI-RS and O-RS are associated with similar rates of recurrence and death in LACC patients managed by surgery after CT/RT. No difference in early or late complications was reported.
放化疗(CT/RT)后行根治性手术(RS)可能适用于对 CT/RT 反应不佳的局部晚期宫颈癌(LACC)患者,或在放疗机会有限的低收入国家。我们的目的是评估微创根治性手术(MI-RS)与开放根治性手术(O-RS)相比的肿瘤学和手术结局。
对接受 CT/RT 和 RS 治疗的 IB2-IVA 期宫颈癌患者的数据进行了回顾性分析。
最初纳入 686 例患者,通过倾向评分匹配得到 462 例患者(每组 231 例),这些患者在 FIGO 分期、淋巴结状态、组织类型、肿瘤分级和 CT/RT 临床反应方面具有可比性。O-RS 组和 MI-RS 组的 5 年无病生存率(DFS)分别为 73.7%和 73.0%(HR 1.034,95%CI 0.708-1.512,p=0.861)。O-RS 组的 5 年局部区域复发率为 12.5%,MI-RS 组为 15.2%(HR 1.174,95%CI 0.656-2.104,p=0.588)。O-RS 组的 5 年疾病特异性生存率(DSS)为 80.4%,MI-RS 组为 85.3%(HR 0.731,95%CI 0.438-1.220,p=0.228)。MI-RS 组的估计失血量较低(p<0.001),住院时间较短(p<0.001)。O-RS 组有 77 例(33.3%)患者发生早期术后并发症,MI-RS 组有 88 例(38.1%)患者发生早期术后并发症(p=0.331)。O-RS 组有 56 例(24.2%)患者发生晚期术后并发症,MI-RS 组有 61 例(26.4%)患者发生晚期术后并发症(p=0.668)。
在接受 CT/RT 后手术治疗的 LACC 患者中,MI-RS 和 O-RS 的复发和死亡发生率相似。报告的早期和晚期并发症无差异。